ENDONOVO THERAPEUTICS, INC. Annual Cost of Revenue in USD from 2018 to 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Endonovo Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from 2018 to 2022.
  • Endonovo Therapeutics, Inc. Cost of Revenue for the quarter ending September 30, 2023 was $827.000, a 79.5% decline year-over-year.
  • Endonovo Therapeutics, Inc. annual Cost of Revenue for 2022 was $9.99K, a 33.3% decline from 2021.
  • Endonovo Therapeutics, Inc. annual Cost of Revenue for 2021 was $15K, a 77.1% decline from 2020.
  • Endonovo Therapeutics, Inc. annual Cost of Revenue for 2020 was $65.4K, a 30% decline from 2019.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $9.99K -$5K -33.3% Jan 1, 2022 Dec 31, 2022 10-K 2023-04-17
2021 $15K -$50.4K -77.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-17
2020 $65.4K -$28K -30% Jan 1, 2020 Dec 31, 2020 10-K 2022-04-14
2019 $93.4K +$80.5K +622% Jan 1, 2019 Dec 31, 2019 10-K 2021-04-13
2018 $12.9K Jan 1, 2018 Dec 31, 2018 10-K 2020-05-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.